As it has been shown previously that the presence of Aβ peptides leads to an aggravation of an existing tau pathology in a variety of transgenic AD mouse models, we evaluated the impact of soluble N-terminally truncated Aβ4-42 peptides in the widely used PS19 mouse model of AD. This evidence concerns the gene MAPT and Alzheimer disease.